Sensome

Sensome is a clinical-stage health technology company founded in 2014 as a spin-off from CNRS and Ecole polytechnique in France. The company focuses on developing micro-sensor technology that enhances invasive medical devices by integrating impedance-based micro-sensors with machine learning algorithms. This technology allows for real-time identification of biological tissues, improving clinical decision-making. The flagship product, Clotild®, is a connected guidewire designed for treating acute ischemic stroke. It analyzes blood clot content during mechanical thrombectomy procedures, helping physicians choose the best tools and strategies for effective clot removal. Sensome's technology has potential applications beyond stroke treatment, including oncology and peripheral artery disease (PAD). The company has secured significant funding, including a $9 million Series B round, to advance its technology and bring Clotild® to market. Sensome collaborates with Asahi Intecc to develop new connected guidewires, combining their sensor technology with Asahi's expertise.

• Employees44
• Founded2014
• Annual Revenue$1000000
• Total Funding$23118053